CY1122531T1 - Νεα χρηση - Google Patents

Νεα χρηση

Info

Publication number
CY1122531T1
CY1122531T1 CY20201100075T CY201100075T CY1122531T1 CY 1122531 T1 CY1122531 T1 CY 1122531T1 CY 20201100075 T CY20201100075 T CY 20201100075T CY 201100075 T CY201100075 T CY 201100075T CY 1122531 T1 CY1122531 T1 CY 1122531T1
Authority
CY
Cyprus
Prior art keywords
nepi
effective amount
angiotensin receptor
patient
inhibitor
Prior art date
Application number
CY20201100075T
Other languages
English (en)
Inventor
Victor Chengwei Shi
Martin Lefkowitz
Adel Remond RIZKALA
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51494327&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1122531(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/US2013/056680 external-priority patent/WO2015030711A1/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1122531T1 publication Critical patent/CY1122531T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε μεθόδους και φαρμακευτικές συνθέσεις για την πρόληψη ή την καθυστέρηση του χρόνου μέχρι την πρώτη εμφάνιση θνησιμότητας, συγκεκριμένα καρδιαγγειακού θανάτου, ή/και καρδιαγγειακών νοσηλειών σε έναν ασθενή που πάσχει από χρόνια συστολική καρδιακή ανεπάρκεια, οι οποίες περιλαμβάνουν χορήγηση μιας θεραπευτικούς αποτελεσματικής ποσότητας, ή μιας προφυλακτικώς αποτελεσματικής ποσότητας, ενός αναστολέα Υποδοχέα Αγγειοτενσίνης Νεπριλυσίνη (ΑRΝi) ή ενός συνδυασμού Δεσμευτή Υποδοχέα Αγγειοτενσίνης (ΑRΒ) με έναν αναστολέα Ουδέτερης Ενδοπεπτιδάσης (ΝΕΡi) ή με ένα προφάρμακο ΝΕΡi στον εν λόγω ασθενή.
CY20201100075T 2013-08-26 2020-01-28 Νεα χρηση CY1122531T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US2013/056680 WO2015030711A1 (en) 2013-08-26 2013-08-26 New use
US201461972933P 2014-03-31 2014-03-31
PCT/IB2014/064074 WO2015028941A1 (en) 2013-08-26 2014-08-26 New use

Publications (1)

Publication Number Publication Date
CY1122531T1 true CY1122531T1 (el) 2021-01-27

Family

ID=51494327

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100075T CY1122531T1 (el) 2013-08-26 2020-01-28 Νεα χρηση

Country Status (15)

Country Link
US (2) US20160213646A1 (el)
EP (3) EP3626270B1 (el)
JP (1) JP6097888B2 (el)
CY (1) CY1122531T1 (el)
DK (2) DK3626270T3 (el)
ES (2) ES2767084T3 (el)
FI (1) FI3626270T3 (el)
HR (2) HRP20240034T1 (el)
HU (2) HUE047186T2 (el)
LT (2) LT3038654T (el)
PL (2) PL3626270T3 (el)
PT (2) PT3038654T (el)
RS (2) RS59816B1 (el)
SI (2) SI3626270T1 (el)
WO (1) WO2015028941A1 (el)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3626270T3 (da) 2013-08-26 2024-01-15 Novartis Ag Behandling af kardiovaskulære sygdomme
EP3253740A1 (en) * 2015-02-06 2017-12-13 Mylan Laboratories Ltd. Amorphous trisodium sacubitril valsartan and a process for the preparation thereof
EP3302460A1 (en) * 2015-05-29 2018-04-11 Novartis AG Sacubitril and valsartan for treating metabolic disease
CN106309388A (zh) * 2015-06-30 2017-01-11 深圳信立泰药业股份有限公司 一种用于心衰治疗的药物组合物及其制备方法
CN106491600A (zh) * 2015-09-06 2017-03-15 常州方楠医药技术有限公司 无定型沙库区比、缬沙坦或其药学上可接受的盐与药用辅料的组合物及其制备方法
WO2017036420A1 (zh) * 2015-09-06 2017-03-09 常州方楠医药技术有限公司 含沙库比曲和缬沙坦的药用组合物及其制备方法
CN107510653A (zh) * 2016-06-17 2017-12-26 常州爱诺新睿医药技术有限公司 一种含有无定型沙库比曲和缬沙坦的固体分散体的药用组合物及其制备方法
WO2017042700A1 (en) * 2015-09-07 2017-03-16 Sun Pharmaceutical Industries Limited Solid forms of valsartan and sacubitril
US20180303799A1 (en) * 2015-10-16 2018-10-25 Shenzhen Salubris Pharmaceuticals Co., Ltd An Oral Preparation for the Treatment of Cardiovascular Disease and Its Preparation Method
CN105330609B (zh) * 2015-12-07 2017-12-22 南京正大天晴制药有限公司 一种制备lcz696的方法
AU2017215530B2 (en) 2016-02-03 2019-09-12 Novartis Ag Galenic formulations of organic compounds
CN106176681A (zh) * 2016-08-25 2016-12-07 泰力特医药（湖北）有限公司 一种抗心脏衰竭药物lcz696口服缓释微丸及其制备方法
WO2019008485A1 (en) 2017-07-06 2019-01-10 Mankind Pharma Ltd FIXED DOSE PHARMACEUTICAL COMPOSITION BASED ON VALSARTAN AND SACUBITRIL
US20210177803A1 (en) * 2018-08-23 2021-06-17 Novartis Ag New pharmaceutical use for the treatment of heart failure
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
JP7316449B2 (ja) * 2019-09-20 2023-07-27 シェンヅェン サルブリス ファーマシューティカルズ カンパニー リミテッド 心不全治療におけるアンジオテンシンｉｉ受容体アンタゴニスト代謝産物とｎｅｐ阻害剤との複合体の使用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122007000050I1 (de) 1990-02-19 2007-11-08 Novartis Ag Acylverbindungen
US5217996A (en) 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
PT966282E (pt) * 1997-01-10 2003-10-31 Merck & Co Inc Uso de antagonistas da angiotensina ii para tratar a insuficiencia cardiaca sintomatica
AU2003206738C1 (en) 2002-01-17 2020-01-30 Novartis Ag Pharmaceutical compositions comprising valsartan and NEP inhibitors
BRPI0410374A (pt) * 2003-05-16 2006-06-13 Novartis Ag composição farmacêutica que compreende valsartano
AR057882A1 (es) * 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
MY153730A (en) 2007-11-06 2015-03-13 Novartis Ag Dual-acting pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitor
CN105214086B (zh) 2008-11-22 2019-09-27 霍夫曼-拉罗奇有限公司 抗-vegf抗体与化学治疗联合用于治疗乳腺癌的应用
EP2608784B1 (en) 2010-08-24 2018-09-19 Novartis AG Treatment or prevention of heart failure in a mammal receiving anti-coagulant therapy
WO2014029848A1 (en) 2012-08-24 2014-02-27 Novartis Ag Nep inhibitors for treating diseases characterized by atrial enlargement or remodeling
EP3038653A1 (en) * 2013-08-26 2016-07-06 Novartis AG New use
DK3626270T3 (da) 2013-08-26 2024-01-15 Novartis Ag Behandling af kardiovaskulære sygdomme

Also Published As

Publication number Publication date
RS65037B1 (sr) 2024-02-29
EP3626270B1 (en) 2023-10-11
US20160213646A1 (en) 2016-07-28
PT3626270T (pt) 2024-01-11
PL3038654T3 (pl) 2020-05-18
SI3626270T1 (sl) 2024-03-29
JP6097888B2 (ja) 2017-03-15
EP3626270A1 (en) 2020-03-25
SI3038654T1 (sl) 2020-02-28
HRP20240034T1 (hr) 2024-03-29
DK3038654T3 (da) 2020-02-03
PL3626270T3 (pl) 2024-04-08
US20210077461A1 (en) 2021-03-18
HUE047186T2 (hu) 2020-04-28
RS59816B1 (sr) 2020-02-28
PT3038654T (pt) 2020-02-04
DK3626270T3 (da) 2024-01-15
WO2015028941A1 (en) 2015-03-05
ES2767084T3 (es) 2020-06-16
EP3038654B1 (en) 2019-10-30
HRP20200060T1 (hr) 2020-04-03
EP3038654A1 (en) 2016-07-06
LT3626270T (lt) 2024-01-25
LT3038654T (lt) 2020-01-27
JP2016528303A (ja) 2016-09-15
ES2968541T3 (es) 2024-05-10
EP4321157A2 (en) 2024-02-14
FI3626270T3 (fi) 2024-01-11
EP4321157A3 (en) 2024-05-15
HUE064634T2 (hu) 2024-04-28

Similar Documents

Publication Publication Date Title
CY1122531T1 (el) Νεα χρηση
CY1121203T1 (el) Θεραπευτικες χρησεις της εμπαγλιφλοζινης
CY1122909T1 (el) Μεθοδοι αντιμετωπισης της ηωσινοφιλικης οισοφαγιτιδας με χορηγηση αναστολεα του ιl-4r
CY1120903T1 (el) Ενωσεις αμινοπυριδυλοξυπυραζολιου
CY1125144T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρηση αυτης
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
CY1122754T1 (el) Μεθοδοι για την αγωγη της ρινικης πολυποδιασης με την χορηγηση ενος ανταγωνιστη il-4r
CY1124928T1 (el) Αναστολεις πυραζολυλο κινοξαλινο κινασης
CY1121853T1 (el) Συνδυαστικη θεραπεια για την αγωγη του διαβητη
BR112016012358A2 (pt) peptídios terapêuticos
CY1122449T1 (el) Σχηματα δοσολογιας ανοσοσυζευγματος enanti-folr1
CY1121419T1 (el) Αναστολη της φουκοσυλιωσης των πρωτεϊνων in vivo χρησιμοποιωντας αναλογα φουκοζης
CY1117678T1 (el) Ενωσεις αναστολεων μεταλλοενζυμου
CY1116803T1 (el) Φαρμακευτικος συνδυασμος για χρηση στον γλυκαιμικο ελεγχο σε ασθενεις με διαβητη τυπου 2
EA201490926A1 (ru) Конструкции на основе белка, родственного липопротеинам низкой плотности, 6 (lrp6), и удлинителя полупериода существования
CR20150120A (es) Nuevos derivados bicíclicos
EA201790765A1 (ru) Производные спиродиамина в качестве ингибиторов альдостерон-синтазы
EA201490644A1 (ru) Терапевтические пептиды
CY1124425T1 (el) Συνθεσεις οι οποιες περιλαμβανουν συζευγματα φαρμακου αντισωματος-δουοκαρμυκινης
CY1117250T1 (el) Λιξισενατιδη και μετφορμινη για τη θεραπευτικη αγωγη διαβητη τυπου 2
CY1123490T1 (el) Συνθεσεις που προερχονται απο χιτοζανη
BR112019007613A2 (pt) terapia de combinação para inibição de c3
DOP2016000070A (es) Inhibidor de grelina o-acil transferasa
CY1120751T1 (el) Αναστολεις ετεροδικυκλοαρυλιου του rorc2 και μεθοδοι χρησης αυτων
EA201590272A1 (ru) Пероральные дозированные формы для модифицированного высвобождения, содержащие руксолитиниб